Abstract
In the last years, PKC has become an attractive target for the treatment of cancer patients given its widely described role in carcinogenesis and tumor promotion. Despite the extensive research conducted on these phorbol ester receptors there is only limited knowledge about the contribution of each individual PKC isozyme in malignant transformation, mainly due to the different roles of each isozyme and their tissue-specificity. This diversity provides the unique opportunity to develop specific pharmacological agents, but the complex nature of the signaling pathways activated by different PKCs challenges selective drug therapies. Currently, several classes of PKC inhibitors including small molecule kinase inhibitors, biologic modulators, and anti-sense oligonucleotides are being evaluated for the treatment of different cancers where PKC isozymes were found to be deregulated as lung, colon, skin, prostate, and breast malignancies. In this article we will review which PKC isoforms are deregulated in different human cancers and summarize the mechanism of action of some of the major PKC modulators, analyzing the strengths and weaknesses of each one in the clinical setting.
Keywords: Cancer, clinical trials, PKC, tumor promotion, malignant transformation, specific pharmacological agents, anti-sense oligonucleotides, protein kinase C (PKC), therapeutic target, cell membrane receptors, several signaling cascades, cell cycle arrest, normal mammary cells, matrix metalloproteinases (MMP)
Current Pharmaceutical Biotechnology
Title: The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Volume: 12 Issue: 11
Author(s): F. Coluccio Leskow, M. A. Krasnapolski and A. J. Urtreger
Affiliation:
Keywords: Cancer, clinical trials, PKC, tumor promotion, malignant transformation, specific pharmacological agents, anti-sense oligonucleotides, protein kinase C (PKC), therapeutic target, cell membrane receptors, several signaling cascades, cell cycle arrest, normal mammary cells, matrix metalloproteinases (MMP)
Abstract: In the last years, PKC has become an attractive target for the treatment of cancer patients given its widely described role in carcinogenesis and tumor promotion. Despite the extensive research conducted on these phorbol ester receptors there is only limited knowledge about the contribution of each individual PKC isozyme in malignant transformation, mainly due to the different roles of each isozyme and their tissue-specificity. This diversity provides the unique opportunity to develop specific pharmacological agents, but the complex nature of the signaling pathways activated by different PKCs challenges selective drug therapies. Currently, several classes of PKC inhibitors including small molecule kinase inhibitors, biologic modulators, and anti-sense oligonucleotides are being evaluated for the treatment of different cancers where PKC isozymes were found to be deregulated as lung, colon, skin, prostate, and breast malignancies. In this article we will review which PKC isoforms are deregulated in different human cancers and summarize the mechanism of action of some of the major PKC modulators, analyzing the strengths and weaknesses of each one in the clinical setting.
Export Options
About this article
Cite this article as:
Coluccio Leskow F., A. Krasnapolski M. and J. Urtreger A., The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798376950
DOI https://dx.doi.org/10.2174/138920111798376950 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Substrate-dependent Inhibition of Hypericin on Human Carboxylesterase 2: Implications
for Herb-drug Combination
Current Drug Metabolism Review of Noscapine and its Analogues as Potential Anti-Cancer Drugs
Mini-Reviews in Organic Chemistry Ultrasound-Targeted Delivery Technology: A Novel Strategy for Tumor- Targeted Therapy
Current Drug Targets Targeting SKCa Channels in Cancer: Potential New Therapeutic Approaches
Current Medicinal Chemistry Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Heptahelical Receptors for Lysolipids in Lymphocytes as Targets for Therapeutic Intervention
Drug Design Reviews - Online (Discontinued) Amyloid-Beta Peptide 1-42 Causes Microtubule Deregulation through N-methyl-D-aspartate Receptors in Mature Hippocampal Cultures
Current Alzheimer Research Targeted Cancer Therapeutics: Biosynthetic and Energetic Pathways Characterized by Metabolomics and the Interplay with Key Cancer Regulatory Factors
Current Pharmaceutical Design Meet the Editorial Board
Current Bioinformatics Nanoparticles as Novel Carrier for Brain Delivery: A Review
Current Pharmaceutical Design Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer
Clinical Cancer Drugs Network Pharmacology of Glioblastoma
Current Drug Discovery Technologies Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer
Current Cancer Drug Targets Radiolabeled Probes Targeting G-Protein-Coupled Receptors for Personalized Medicine
Current Pharmaceutical Design Curcumin Sensitizes Cancers Towards TRAIL-induced Apoptosis via Extrinsic and Intrinsic Apoptotic Pathways
Current Drug Targets Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets Evaluation of Natural and Synthetic Compounds from East Asiatic Folk Medicinal Plants on the Mediation of Cancer
Anti-Cancer Agents in Medicinal Chemistry Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Exploring Nanotechnologies for the Effective Therapy of Malaria Using Plant-Based Medicines
Current Pharmaceutical Design